Key Points
- CEO Vishwas Seshadri sold 25,000 shares of Abeona on Dec. 29 at an average price of $5.31 for $132,750, reducing his stake by 2.10% to 1,164,818 shares (valued at about $6.19M); he also sold 25,000 shares on Sept. 30 and 249 shares on Oct. 16.
- Abeona trades with a market cap of $291M and a P/E of 4.37, a 52-week range of $3.93–$7.54 and strong liquidity ratios (quick ratio 9.53), institutional ownership of ~80.6%, and a consensus analyst rating of "Moderate Buy" with a $20 price target.
Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) CEO Vishwas Seshadri sold 25,000 shares of the company's stock in a transaction on Monday, December 29th. The stock was sold at an average price of $5.31, for a total value of $132,750.00. Following the completion of the sale, the chief executive officer owned 1,164,818 shares of the company's stock, valued at $6,185,183.58. This trade represents a 2.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Vishwas Seshadri also recently made the following trade(s):
- On Thursday, October 16th, Vishwas Seshadri sold 249 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.49, for a total value of $1,367.01.
- On Tuesday, September 30th, Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.24, for a total value of $131,000.00.
Abeona Therapeutics Stock Performance
Shares of ABEO opened at $5.37 on Tuesday. The business has a 50-day simple moving average of $4.93 and a two-hundred day simple moving average of $5.72. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06. Abeona Therapeutics Inc. has a 52 week low of $3.93 and a 52 week high of $7.54. The stock has a market cap of $291.00 million, a price-to-earnings ratio of 4.37 and a beta of 1.12.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.17. On average, analysts expect that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.
Institutional Trading of Abeona Therapeutics
Hedge funds have recently bought and sold shares of the stock. Intech Investment Management LLC boosted its holdings in shares of Abeona Therapeutics by 19.6% during the 3rd quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company's stock valued at $133,000 after purchasing an additional 4,127 shares during the last quarter. Creative Planning lifted its position in shares of Abeona Therapeutics by 43.0% in the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company's stock worth $81,000 after buying an additional 4,305 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in Abeona Therapeutics during the second quarter valued at approximately $25,000. Legal & General Group Plc purchased a new position in Abeona Therapeutics during the 2nd quarter valued at approximately $27,000. Finally, Riverwater Partners LLC grew its holdings in Abeona Therapeutics by 45.6% during the 3rd quarter. Riverwater Partners LLC now owns 15,857 shares of the biopharmaceutical company's stock valued at $84,000 after buying an additional 4,963 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company's stock.
Analyst Ratings Changes
A number of research firms recently weighed in on ABEO. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Abeona Therapeutics in a research note on Monday, October 13th. Weiss Ratings cut Abeona Therapeutics from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, October 24th. Finally, Wall Street Zen lowered Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.00.
Read Our Latest Report on Abeona Therapeutics
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
